Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials

Key Points

• The study aims to evaluate the efficacy of semaglutide in reducing HbA1c and body weight in young adults with Type 2 diabetes.
• Post hoc analysis of SUSTAIN and PIONEER clinical trials.
• Assessment of HbA1c and body weight changes in participants.
• Comparison of outcomes across different age subgroups.
• Semaglutide significantly reduced HbA1c levels in young adults.
• Weight loss was observed consistently across all age groups.
• Reducing HbA1c and weight may lower future health complications in younger individuals with T2D.